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Abstract: 
A biocompatible polyester dendrimer composed of the natural
 
metabolites, glycerol and succinic acid, is 
described for the
 
encapsulation of the antitumor camptothecins, 10-hydroxycamptothecin
 
and 7-butyl-10-
aminocamptothecin. The cytotoxicity of the dendrimer-drug
 
complex toward four different human cancer cell 
lines [human
 
breast adenocarcinoma (MCF-7), colorectal adenocarcinoma (HT-29),
 
non–small cell lung 
carcinoma (NCI-H460), and glioblastoma
 
(SF-268)] is also reported, and low nmol/L IC50 values are measured.
 
Cellular uptake and efflux measurements in MCF-7 cells show
 
an increase of 16-fold for cellular uptake and an 
increase in
 
drug retention within the cell when using the dendrimer vehicle. 
 
Article: 
Introduction 
In developed countries, cancer represents the second leading
 
cause of death, exceeded only by heart disease. 
Despite the
 
litany of improvements made in cancer diagnosis, treatment,
 
and prognosis since President Nixon 
first declared a "War on
 
Cancer" in 1971, 1,500 people die from cancer every day in the
 
U.S., with the four 
deadliest cancers being lung, colon, breast,
 
and pancreatic (1). Today, there are a multitude of research
 
efforts 
aimed at improving patient survival, including, among
 
many others, the search for new natural products, the 
synthesis
 
of chemotherapeutic agents, the development of improved anticancer
 
drug delivery methods, and the 
understanding of how cancers
 
originate, grow, and metastasize.
 
 
Natural products have been a very successful source of new antineoplastic
 
agents, contributing to >60% of the 
anticancer pharmaceuticals
 
in use today (2). Of these, two analogues of camptothecin, an
 
alkaloid isolated from 
Camptotheca acuminata reported in 1966
 
(3), are increasingly in clinical use (4–7). Camptothecins
 
have had 
their greatest utility in treating primary and metastatic
 
colon carcinoma, platinum-refractory ovarian cancer, and 
small
 
cell lung carcinoma. Of the $9 billion annual market for cancer
 
chemotherapeutics in 2004, the Food and 
Drug Administration
 
(FDA)–approved camptothecins, topotecan and irinotecan
 
(Fig. 1 ), accounted for >$1 
billion, indicative of their
 
growing use by tens of thousands of individuals (4).
 
 
 
Figure 1. Top, chemical structures of (1) 10-hydroxycamptothecin (10HCPT), (2) 7-butyl-10-
aminocamptothecin (BACPT), (3) topotecan (Hycamtin), and (4) irinotecan (Camptosar). Bottom, chemical 
structure of the [G4.5]-PGLSA-COONa dendrimer with encapsulated 10HCPT (1). Not drawn to scale. 
 
Like many natural products, one of the major anticancer benefits
 
of camptothecin research has been the 
elucidation of its unique
 
and novel mode of action, which is the poisoning of DNA topoisomerase
 
I during its 
catalytic cycle of DNA relaxation (8–10).
 
As a pharmaceutical candidate, however, camptothecin did not
 
have 
optimal properties, particularly with respect to aqueous
 
solubility, and failed in clinical trials conducted in the 
1970s
 
(4). Besides the two aforementioned water-soluble analogues
 
that are currently approved by the FDA, 
there were at least
 
a dozen other analogues of camptothecin in clinical trials as
 
of 2003 (11). Many of these new 
analogues attempt to circumvent
 
the poor water solubility of camptothecins while retaining anticancer
 
potency 
and, importantly, minimizing its side effects (12).
 
Although irinotecan and topotecan continue to find growing 
use
 
in clinical oncology, major side effects caused by the water-solubilizing
 
functionalities include severe (grade 
3) to life-threatening
 
(grade 4) diarrhea and myelosuppression, respectively, which
 
are the primary dose-limiting 
toxicities associated with these
 
treatments (13, 14). Because of these inadequacies, there is
 
significant incentive 
to develop alternative prodrugs or drug
 
delivery systems for camptothecins that will reduce side effects
 
and 
enhance potency.
 
 
As mentioned above, camptothecins, like a large number of highly
 
active pharmaceuticals, lack appreciable 
water solubility. Therefore,
 
these drugs are either not used clinically, delivered in large
 
volumes of aqueous 
solution, delivered in conjunction with surfactants
 
(e.g., Cremophor EL), chemically derivatized to afford 
soluble
 
prodrugs, or linked to large water-soluble polymers (e.g., PEGylation),
 
all of which may result in side 
effects or reduced anticancer
 
efficacy (15, 16).
 
 
Approaches to delivering unaltered natural products using polymeric
 
carriers is of widespread interest (17, 18). 
Recently, dendritic
 
polymers (19–25) have been explored for the encapsulation
 
of hydrophobic compounds and 
for the delivery of anticancer
 
drugs. Dendrimers are globular, highly branched macromolecules
 
possessing a 
well-defined core, an interior region, and a large
 
number of end groups. The physical characteristics of 
dendrimers,
 
including their monodispersity, water solubility, encapsulation
 
ability, and large number of 
functionalizable peripheral groups,
 
make these macromolecules ideal candidates for evaluation as
 
drug delivery 
vehicles. Several previous reviews have covered
 
the early work of drug delivery with dendrimers (25, 26). 
Currently,
 
there are three methods for using dendrimers in drug delivery:
 
(a) the drug is covalently attached to 
the periphery of the
 
dendrimer to form dendrimer prodrugs, (b) the drug is coordinated
 
to the outer functional 
groups via ionic interactions, or (c)
 
the dendrimer acts as a unimolecular micelle by encapsulating
 
a 
pharmaceutical through the formation of a dendrimer-drug (i.e.,
 
host–guest) supramolecular assembly.
 
 
The latter approach is of interest for multiple reasons and
 
provides an opportunity to encapsulate 
pharmacologically active
 
compounds and to study the supramolecular assemblies formed
 
in these systems. For 
example, rose bengal (27) and acetylsalicylic
 
acid (28) have been noncovalently encapsulated within 
poly(propylene
 
imine) and poly(amidoamine) dendrimers. In the case of rose
 
bengal, the internalized dye 
molecules were confined within
 
the dendrimer as a consequence of steric congestion at the dendrimer
 
periphery 
(27). Pyrene was encapsulated within both poly(propylene
 
imine) dendrimers and unimolecular micelles based 
on PEGylated
 
Fréchet-type dendrimers (29, 30). Additionally, fluorescent
 
dyes such as phenol blue (31) and 4-
(dicyanomethylene)-2-methyl-6-(4-dimethylaminostyril)-4H-pyrane
 
(32) have been encapsulated. In a further 
example, poly(amidoamine)
 
dendrimers have been used to enhance the delivery of ibuprofen
 
to A549 lung 
epithelial cells (33).
 
 
We are synthesizing and evaluating dendrimers composed of natural
 
metabolites such as glycerol and succinic 
acid for medical uses
 
(34–39). We have found that crosslinkable derivatives
 
of these dendrimers are useful for 
the repair of ophthalmic
 
wounds and articular cartilage (35, 37, 40–42). Recently,
 
we described the 
encapsulation characteristics of a poly(glycerol-succinic
 
acid) (PGLSA) dendrimer and the use of this 
macromolecule as
 
a potential vehicle for drug delivery (43). In this report,
 
we expand on the potential use of 
these polyester dendrimers
 
for the delivery of potent and poorly water-soluble anticancer
 
drugs, like the 
camptothecins. These PGLSA dendrimers are attractive
 
for cancer therapy because: (a) the chemical 
composition, physical
 
structure, and molecular weight can be precisely controlled;
 
(b) the dendrimer structure 
permits diverse and extensive site-specific
 
functionalization; (c) the container-like properties enable
 
the 
entrapment and delivery of poorly water-soluble anticancer
 
agents; and (d) the potential for enhanced uptake of 
the dendrimer
 
in specific cell lines or reduced drug efflux from the cells.
 
Herein, we report the encapsulation of 
10-hydroxycamptothecin
 
(10HCPT) and 7-butyl-10-aminocamptothecin (BACPT) within PGLSA
 
dendrimers 
and the cytotoxicity of these supramolecular assemblies
 
towards human breast adenocarcinoma (MCF-7), 
colorectal adenocarcinoma
 
(HT-29), non–small cell lung carcinoma (NCI-H460), and
 
glioblastoma (SF-268) 
cell lines. We also report the effect
 
of encapsulating 10HCPT within PGLSA dendrimers on drug uptake
 
and 
efflux rates when exposed to MCF-7 cells.
 
 
Materials and Methods 
Chemicals and Instrumentation 
All solvents were dried and freshly distilled prior to use (pyridine
 
with CaH and THF with Na). All chemicals 
were purchased from
 
Aldrich or Acros at the highest purity grade available and used
 
without further 
purification. All reactions were done under
 
nitrogen atmosphere at room temperature unless specified otherwise.
 
Nuclear magnetic resonance (NMR) spectra were recorded on a
 
Varian INOVA spectrometer (operating at 400 
and 100.6 MHz for
 1
H and 
13
C NMR, respectively). Fourier transform IR (FTIR) spectra
 
were recorded on a 
Nicolet Smart MIRacle Avatar 360 using a
 
zinc selenide crystal. MALDI-TOF mass spectra were obtained
 
using 
a PerSpective Biosystems Voyager-DE Biospectrometry Workstation
 
operating in the positive ion mode using 
2-(4-hydroxyphenylazo)-benzoic
 
acid. UV-Vis spectra were recorded on a Hewlett Packard 8453
 
spectrophotometer. Fluorescence spectra were acquired on a Photon
 
Technology International QM-4/2005 
spectrofluorimeter. cLogP
 
values were calculated using the ACD/LogP DB, version 9.09 (Advanced
 
Chemistry 
Development, Inc., Toronto, Ontario, Canada).
 
 
Synthesis 
10HCPT was isolated from C. acuminata (44) and BACPT was synthesized
 
as described recently (45). The 
synthesis of the hydroxyl-terminated
 
generation four-PGLSA dendrimer, [G4]-PGLSA-OH, was carried
 
out as 
described in a previous publication (34). The synthesis
 
of the carboxylated derivative of the [G4]-PGLSA-OH, 
which was
 
used in this study, is described below.
 
 
Synthesis of [G4.5]-PGLSA-COONa. [G4]-PGLSA-OH (0.140 g, 0.0131
 
mmol) was dissolved in pyridine (10 
mL) and stirred while succinic
 
anhydride (0.167 g, 1.68 mmol) was added. The reaction mixture
 
was stirred for 
16 hours before the pyridine was removed under
 
reduced pressure. The contents were partially dissolved in 
CH2Cl2
 
(15 mL), 0.1 N HCl (15 mL) was added, and then the mixture was
 
stirred for an additional 15 minutes. 
After stirring, the organic
 
and aqueous phases separated, and a layer was formed between
 
the two phases. 
Although avoiding the interface, most of the
 
aqueous and organic phases were removed. This washing 
procedure,
 
using 15 mL of CH2Cl2 and 0.1 N of HCl, was repeated twice.
 
Any remaining organic or aqueous 
phase was removed first by
 
rotoevaporation followed by lyophilization to yield 0.191 g
 
of a highly viscous 
liquid (85% yield). To dissolve the dendrimer
 
in water, deionized water (10 mL) and brine (0.5 mL) were added
 
to the solution, and 0.05 N of NaOH was added drop-wise to the
 
stirring solution until the pH remained at 7.0. 
The dendrimer
 
was purified via dialysis with 7,000 molecular weight cutoff
 
dialysis tubing for 24 hours in 
deionized water. The water was
 
then removed via lyophilization to obtain a white solid. 
1
H-NMR
 
(D2O): 2.32 
(m, 130, -CH2-CH2-), 2.46 (m, 133, -CH2-CH2-),
 
2.58 (m, 228, -CH2-CH2-) 4.13 to 4.21 (m, 240, -CH2-CH-
CH2-),
 
5.18 (m, 62, -CH2-CH-CH2-). 
13
C NMR (D2O): 180.72 (COOH), 175.37
 
(COOH), 173.52 (COOR), 
70.14 (CH), 69.76 (CH), 62.80 (CH2),
 
34.31 (CH2), 32.10 (CH2), 30.72 (CH2), 29.01 (CH2). FTIR: (cm
–1
)
 
3,368 (OH), 2,964 (aliphatic C-H stretch), 1,732 (C = O), 1,567
 
(asymmetric COO
–
 stretch), 1,409 (symmetric 
COO
– 
stretch), 1,149 (C-O stretch). MALDI mass spectrometry 17,168
 
m/z (M + Na)
+
, 8602 m/z (M + Na)
2+
 
[theory, 17,120.0 m/z (M
+
)].
 
 
Encapsulation Procedure 
The encapsulation procedure requires both the dendrimer and
 
hydrophobic compound to be soluble in a volatile 
organic solvent
 
that is miscible with water.
 
 
10HCPT encapsulated within [G4.5]-PGLSA-COONa. For molar calculations,
 
we assumed a molecular 
weight of 17,823 for the dendrimer, corresponding
 
to a half-protonated/half-sodium salt carboxylic acid–
terminated
 
dendrimer. Twenty-five milligrams (1.4 x 10–6 mol) of the [G4.5]-PGLSA-COONa dendrimer was 
dissolved in 2.0 mL of
 
CH3OH. A solution of 10HCPT (0.5 mg/1.4 x 10
–6
 mol) in
 
1.0 mL of CH3OH was added 
to the dendrimer solution and stirred
 
for 10 minutes. Next, 1.0 mL of water was added to the CH3OH
 
solution 
and stirred for 1 hour. The uncovered solution was
 
then stirred overnight in the dark to allow the CH3OH to 
slowly
 
evaporate. The remaining CH3OH was removed via rotary evaporation
 
over several hours. A small 
amount of drug precipitated from
 
the solution and was removed via centrifugation. The concentration
 
of the 
encapsulated 10HCPT was measured via UV-Vis ( max = 382
 
nm; 382 = 28,000) and was found to be 240 
µmol/L. The
 
encapsulated drug-dendrimer solution was then stored in the
 
dark, at room temperature, until 
further use. All experiments
 
were done within 24 hours of preparing the sample. A similar
 
procedure was used 
for encapsulating BACPT and the concentration
 
of encapsulated BACPT was determined to be 440 µmol/L
 
(
max = 339 nm; 339 = 15,020). Samples for NMR analysis were
 
prepared using deuterated solvents.
 
 
NMR Experiments 
NMR data on the encapsulated species were recorded at 25°C
 
in 5 mm NMR tubes using Varian Inova 500 and 
600 MHz NMR spectrometers
 
with 5 mm Varian probes. The 500 MHz 
1
H-NMR spectra of the drug,
 
dendrimer, and drug-dendrimer complex were obtained with a spectral
 
width of 5.5 kHz, a 77-degree pulse flip 
angle (5 µs),
 
a 5.8 second acquisition time, 1 second relaxation delay, and
 
digitized using 64,000 points to 
obtain a digital resolution
 
of 0.17 Hz/pt. One-dimensional difference NOE spectra (NOEDS)
 
for the 
dendrimer/BACPT sample were generated from a spectrum
 
recorded with a 6.5-second selective on-resonance 
irradiation
 
of a succinic acid methylene signal at an estimated power level
 
of 0.1 mW and a 5.8-second 
acquisition period to build up the
 
steady state NOE and a control spectrum irradiated off-resonance
 
of the 
methylene signal. Suppression of the water signal was
 
achieved with a separate 1.5-second long presaturation 
pulse
 
at the water frequency incorporated within the 6.5-second irradiation
 
period. To improve free induction 
decay (FID) subtraction, the
 
dendrimer/BACPT sample was equilibrated in the magnet for 30
 
minutes before 
recording data. The NOEDS were obtained in an
 
interleaved manner with eight scans accumulated for the on-
 
or 
off-resonance FID and looping around 128 times to achieve
 
a good signal-to-noise ratio with 1,024 scans per 
FID.
 
 
Human Cancer Cell Panel 
The cytotoxicity of 10HCPT, BACPT, and their corresponding dendrimer
 
encapsulation formulations were 
evaluated in a human cancer
 
cell panel using a procedure described previously (46). MCF-7
 
human breast 
carcinoma (Barbara A. Karmanos Cancer Center, Detroit,
 
MI), NCI-H460 human large cell lung carcinoma 
(American Type
 
Culture Collection, Manassas, VA), and SF-268 human astrocytoma
 
(NCI Developmental 
Therapeutics Program, Frederick, MD) cell
 
lines were all adapted and maintained in RPMI 1640 supplemented
 
with fetal bovine serum (Life Technologies/Invitrogen, Carlsbad,
 
CA) at 10% (v/v) and the antibiotics, 
penicillin G (100 units/mL)
 
and streptomycin sulfate (100 µg/mL), in a humidified
 
5% CO2 atmosphere kept at 
37°C. HT-29 human colorectal adenocarcinoma
 
cells (American Type Culture Collection) were maintained in
 
McCoy's 5A medium (Life Technologies/Invitrogen) under the same
 
conditions described above. Strict 
attention was paid to using
 
cells when in the logarithmic phase of cell growth. Cells were
 
harvested from 
subconfluent cultures using trypsin/EDTA (0.05%/0.02%)
 
and were suspended in medium. Cell viability was 
determined
 
using a sulforhodamine B (SRB) protein binding assay.
 
 
Cell suspensions were first prepared at densities of 3,000 (MCF-7),
 
1,500 (NCI-H460), 10,000 (SF-268), or 
4,000 (HT-29) cells per
 
50 µL of medium for each well of 96-well culture dishes.
 
The medium of each well was 
then replaced with 100 µL
 
of antibiotic-free medium containing various concentrations
 
of the dendrimer, free 
camptothecin, or dendrimer-encapsulated
 
camptothecin. Three replicates were tested for each concentration.
 
For 
IC50 determinations, the formulations were diluted serially
 
in half-log steps. Blank wells and wells with media 
but no cells
 
were included for background correction because trichloroacetic
 
acid (TCA)–precipitated proteins 
from serum alone result
 
in some background SRB absorbance.
 
 
After a 3-day continuous exposure, cells were fixed by the addition
 
of 25 µL of cold 50% (w/v) TCA to the 
growth medium in
 
each well at 4°C for 1 hour, then washed five times with
 
water. The TCA-fixed cells were 
then stained for 30 minutes
 
with 50 µL of 0.4% (w/v) SRB in 1% (v/v) acetic acid followed
 
by five rinses with 
1% (v/v) acetic acid to remove unbound dye.
 
The fixed, stained plates were air-dried and bound dye was then
 
solubilized by incubation with 100 µL of 10 mmol/L Tris
 
base for at least 5 minutes. Absorbance was measured 
at 540
 
nm using a Tecan Ultra multiplate reader. Absorbance measured
 
on wells containing cells that did not 
receive the drug represented
 
100% growth, and absorbance measured on wells containing no
 
cells represented 
0% growth. For IC50 calculations, survival
 
data were evaluated by variable slope curve-fitting using Prism
 
4.0 
software (GraphPad, San Diego, CA).
 
 
Cell Uptake and Efflux Studies 
The intracellular accumulation and retention of 10HCPT with
 
and without dendrimer encapsulation was 
measured. MCF-7 cells
 
were plated into 12-well plates at a density of 3 x 105 cells/well and incubated overnight 
before cell uptake and efflux experiments.
 
The medium from each well was replaced with 1 mL of medium 
containing
 
either free 10HCPT or dendrimer-encapsulated 10HCPT at a drug
 
concentration of 1, 5, or 8 µmol/L. 
In the first set of
 
trials, the cellular uptake of both free and dendrimer-encapsulated
 
10HCPT was measured. 
After 2, 10, or 24 hours of drug exposure,
 
the medium was removed, and the attached cells were washed directly
 
with PBS and lysed with 200 µL of DNase I lysis buffer
 
[20 mmol/L Tris-HCl (pH 7.5), 50 mmol/L NaCl, 5 
mmol/L MgCl2,
 
5% glycerol, 0.05 mg/mL DNase I, 0.25% (w/v) SDS, and 10 mmol/L
 
DTT; ref. 47]. No 
floating cells were detectable in these studies,
 
even after 24 hours of treatment with the highest drug 
concentration.
 
 
In the second set of experiments, the retention of both free
 
and dendrimer-encapsulated 10HCPT was measured. 
MCF-7 cells
 
were exposed to medium containing either 10HCPT or dendrimer-encapsulated
 
10HCPT at a 
concentration of 1, 5, or 8 µmol/L for 24
 
hours. At the end of 24 hours of drug exposure, the medium was
 
removed, cells washed with PBS, and then replaced with fresh
 
medium devoid of 10HCPT or dendrimer-
encapsulated 10HCPT. At
 
0.5, 8, or 32 hours after incubation in the drug-free media,
 
the medium was removed 
and floating cells were recovered by
 
centrifugation at 1,000 x g for 5 minutes. The cell monolayer was washed 
with PBS as above and the floating cell pellet was
 
lysed together with the monolayer using the DNase I lysis 
buffer
 
(47) described above.
 
 
In both sets of experiments, the concentrations of 10HCPT in
 
the cell lysate samples were determined 
fluorometrically using
 
a standard curve via excitation at 382 nm, and measuring the
 
emission at 550 nm. 
Fluorescence spectroscopy was used instead
 
of UV-Vis spectroscopy for better accuracy at low concentration.
 
 
Results and Discussions 
Encapsulation studies. The carboxylate-terminated fourth generation
 
[G4.5]-PGLSA-COONa dendrimer (Fig. 
1) was used in these encapsulation
 
studies because it provided better encapsulation characteristics
 
than the 
smaller generation dendrimers and the hydroxy-terminated
 
dendrimers (43). The [G4.5]-PGLSA-COONa 
dendrimer was synthesized
 
and possessed a molecular weight of 17,823 (half sodium salt).
 
It was fully 
characterized by NMR, FTIR, and MALDI-TOF mass
 
spectrometry.
 
 
10HCPT (1) and BACPT (2) were selected for encapsulation because:
 
(a) both camptothecins possess poor 
aqueous solubility (<25
 
µmol/L), (b) BACPT is more lipophilic than 10HCPT based
 
on cLogP of 3.14 versus 
1.63, respectively, (c) 10HCPT and BACPT
 
exhibit different cell line cytotoxicity profiles, and (d) BACPT
 
is 
more cytotoxic than 10HCPT.
 
 
The encapsulation procedure required both the dendrimer and
 
the hydrophobic camptothecin to be soluble in a 
volatile organic
 
solvent that is miscible with water. Briefly stated, a 1:1 molar
 
ratio of the dendrimer and drug 
was dissolved in methanol and
 
water, and then the methanol was removed to afford the dendrimer-encapsulated
 
camptothecin. The concentration of the encapsulated 10HCPT was
 
determined to be 240 µmol/L, which 
represents an 10-fold
 
increase in the water solubility of 10HCPT ( 20 µmol/L).
 
The concentration of 
encapsulated BACPT was determined to be
 
440 µmol/L, an 10-fold increase in the water solubility
 
of BACPT 
( 40 µmol/L).
 
 
To assess the drug release profile of the encapsulated 10HCPT/[G4.5]-PGLSA-COONa
 
vehicle, we monitored 
the release of 10HCPT in PBS buffer at
 
a pH of 7.4. Specifically, a solution of dendrimer-encapsulated
 
10HCPT 
was prepared using the encapsulation procedure described
 
previously, and the drug concentration in the solution 
was determined
 
to be 218 µmol/L. Next, a 100 µL aliquot of the
 
dendrimer-encapsulated 10HCPT was added to 
3 mL of PBS buffer
 
and subsequently transferred into a dialysis cassette (0.5–3
 
mL, Slide-A-Lyser; Pierce, 
Rockford, IL) with a molecular weight
 
cutoff of 3,500. The dialysis cassette was then placed into
 
a beaker 
containing 100 mL of PBS buffer at 37°C. Next,
 
200 µL aliquots of the buffer were removed from the beaker
 
at 
different time points over the next 30 hours. The concentration
 
of 10HCPT in the buffer aliquots at each time 
point was determined
 
by fluorescence spectroscopy ( Ex = 382 nm and Em = 550 nm).
 
A series of nine samples 
having known concentrations of 10HCPT
 
were used to create a calibration curve from which the concentrations
 
of the unknown samples were determined. This experiment was
 
done in duplicate. The results are displayed in 
Fig. 2 and
 
show that the drug is released relatively linearly over the
 
first 2 hours and reaches full release at 6 
hours. Based on
 
the release profile, the dendrimer vehicle is likely to be more
 
effectively used for intratumoral 
delivery instead of i.v.
 
 
 
Figure 2. [G4.5]-PGLSA-COONa encapsulated 10HCPT release profile. Points, mean; bars, range (n = 2). 
 
NMR characterization of dendrimer-encapsulated camptothecins.
 
To further characterize the 
supramolecular assembly formed between
 
the dendrimer and the camptothecin analogues, we did a series
 
of 
NMR experiments. In the 
1
H-NMR spectra, the aromatic protons
 
of the encapsulated 10HCPT and BACPT are 
distinct and downfield
 
from the dendrimer protons. Selective irradiation of the internal
 
succinic acid protons of 
the dendrimer reveals NOE dipolar interactions
 
to the aromatic proton resonances of the camptothecins. As 
shown
 
in Fig. 3 , the NOEDS, with selective irradiation of the internal
 
succinic acid protons (2.68 ppm), reveal 
NOE dipolar interactions
 
in four of the nine proton resonances of BACPT. Similar results
 
were observed and 
reported previously with the encapsulated
 
10HCPT (data not shown; ref. 43). These data suggest internalization
 
of the camptothecins within the dendrimer structure and not
 
localization at the periphery. These findings were 
supported
 
by performing a similar experiment on the peripheral succinic
 
acid protons (2.55 ppm), which when 
irradiated, did not generate
 
selective NOEs to the aromatic protons of 10HCPT or BACPT. 
 
 
Figure 3. Top, 
1
H-NMR spectrum of BACPT encapsulated within [G4.5]-PGLSA-COONa (D2O, ppm from 
TMS) in which the singlet and doublet in the aliphatic region (2–3 ppm) correspond to the interior and exterior 
succinic acid protons of the dendrimer, respectively (inset, expansion of aromatic region). Bottom, one-
dimensional 
1
H-NOEs (A) between encapsulated BACPT (B) and interior succinic acid protons of [G4.5]-
PGLSA-COONa. 
 
Cytotoxicity studies (human colorectal adenocarcinoma, breast
 
adenocarcinoma, non–small cell lung 
carcinoma, and glioblastoma
 
cells). Cytotoxicity experiments were done using standard NCI
 
assay methods, 
which involved a 3-day drug exposure, followed
 
by cellular fixation and quantification of cell survival by
 
staining with SRB, and monitoring the absorbance at 562 nm.
 
Studies were initiated with the HT-29 human 
colorectal adenocarcinoma
 
line, a p53-null line representing one of the most common indications
 
for currently 
FDA-approved camptothecins. To do so, a series
 
of vehicle controls and controls relative to the encapsulated
 
camptothecins were generated, specifically: (a) 10HCPT dissolved
 
in DMSO for both stock solution and 
subsequent dilutions—"DMSO";
 
(b) 10HCPT dissolved in DMSO with subsequent dilutions using
 
distilled, 
deionized water—"DMSO/Water"; (c) 10HCPT dissolved
 
in DMSO and then simply diluted in water already 
containing
 
the dendrimer—"Simple mix"; and (d) 10HCPT encapsulated
 
within the dendrimer using the solvent 
evaporation technique
 
followed by vehicle dilution in aqueous solution—"Encapsulated."
 
In addition, the 
dendrimer alone was tested in aqueous solution
 
at a concentration of 0.34 mg/mL, which is higher than the drug
 
delivery studies. The dendrimer alone was not cytotoxic (98.1
 
± 1.8% survival, in quadruplicate in each of three 
experiments).
 
 
The results of a single representative experiment with 10HCPT
 
in HT-29 cells are shown in Fig. 4 . The IC50 of 
the dendrimer-10HCPT
 
assembly was 32.3 nmol/L. This dendrimer-10HCPT assembly had
 
a 3.5-fold increase 
in potency relative to DMSO-dissolved 10HCPT
 
and a 4.1-fold increase in comparison to DMSO-dissolved 
10HCPT
 
stock with subsequent dilutions made in water. This experiment
 
was repeated twice with another 
preparation of dendrimer-encapsulated
 
drug, and the same activity trend of enhanced potency relative
 
to DMSO 
preparations was observed. DMSO was used in these experiments
 
to increase the solubility of 10HCPT, but this 
approach is not
 
acceptable for clinical use.
  
 
Figure 4. Columns, IC50 values (in nanomolar) of different 10HCPT formulations toward HT-29 cells. 
To determine whether the increase in anticancer activity conferred
 
by the dendrimer-encapsulated 10HCPT was 
observed with other
 
cell lines, the 10HCPT dissolved in DMSO and the dendrimer-encapsulated
 
10HCPT 
formulations were compared in a diverse human cancer
 
cell panel (Fig. 5 ). This cell line panel consists of the
 
MCF-7 human breast adenocarcinoma, the NCI-H460 human large
 
cell lung carcinoma, and the SF-268 human 
astrocytoma. Data
 
are expressed as the IC50 values for each drug using a standard
 
3-day continuous exposure 
followed by fixation and SRB staining.
 
Interestingly, the dendrimer-encapsulated 10HCPT exhibited an
 
improved degree of potency relative to the DMSO-dissolved drug
 
in each cell line. Specifically, the IC50 values 
for the DMSO
 
dissolved 10HCPT compared with the dendrimer-encapsulated 10HCPT
 
was reduced from 72.0 
to 10.1 nmol/L for the MCF-7-treated cells,
 
from 32.4 to 16.7 nmol/L for the NCI-H460-treated cells, and
 
from 
13.1 to 4.6 nmol/L for the SF-268-treated cells. Four important
 
observations were noted: first, the use of the 
dendrimer lowered
 
the IC50s compared with the 10HCPT dissolved in DMSO (e.g.,
 
2- to 7-fold); second, the 
magnitude of effect with the dendrimer
 
carrier is not the same for each cell line; third, the greatest
 
magnitude of 
enhanced potency was in the least sensitive cell
 
line (MCF-7); and fourth, potentially clinically relevant, IC50s
 
(<20 nmol/L) were observed for three distinct cancer cell
 
lines. 
 
Figure 5. Top, anticancer activity of dendrimer-encapsulated 10HCPT versus DMSO-dissolved 10HCPT 
expressed as IC50 values (in nanomolar). Bottom, anticancer activity of dendrimer-encapsulated BACPT versus 
DMSO-dissolved BACPT expressed as IC50 values (in nanomolar). Columns, mean; bars, SD (n = 3). 
We next evaluated a more lipophilic camptothecin analogue, BACPT,
 
which possesses an 10-fold greater 
cytotoxic activity in most
 
tumor cell lines as compared with 10HCPT (Fig. 1), possibly
 
due to structural 
characteristics that enhance the interaction
 
with DNA topoisomerase I (45). Due to its limited aqueous solubility
 
BACPT, like 10HCPT, is a challenge in pharmaceutical formulation
 
and subsequent use in the clinic. The 
dendrimer encapsulation
 
process afforded an even greater aqueous solubility to the BACPT
 
of 440 µmol/L 
(relative to 10HCPT). This result suggests
 
that the dendrimer may be of significant utility to improving
 
the 
aqueous solubility of other camptothecin analogues.
 
 
Surprisingly, unlike the case with 10HCPT, the dendrimer encapsulation
 
afforded no additional increment of 
cytotoxicity toward HT-29
 
cells relative to DMSO-dissolved drug: 11.9 nmol/L in DMSO versus
 
10.0 nmol/L 
encapsulated in dendrimer (Fig. 5). However, like
 
10HCPT, it is notable that BAPCT is not used clinically, 
likely
 
due to negligible aqueous solubility. Thus, encapsulation within
 
the dendrimer formulation maintains an 
aqueous bioactivity similar
 
to that in DMSO, thereby overcoming a major challenge in the
 
potential clinical 
utility of this compound.
 
 
To determine whether the lack of additional enhancement of BACPT
 
activity conferred by the dendrimer was 
common to the other
 
three cell lines investigated, the BACPT dissolved in DMSO and
 
dendrimer-encapsulated 
BACPT preparations were compared in the
 
human cancer cell panel as described earlier (Fig. 5). As before,
 
these data are expressed as the IC50 values for each compound
 
using a standard 3-day continuous exposure 
followed by fixation
 
and SRB staining. The dendrimer-encapsulated BACPT exhibited
 
an improved degree of 
potency relative to the DMSO-dissolved
 
agent in each of the other cell lines. Comparing the DMSO-dissolved
 
BACPT to the dendrimer-encapsulated BACPT, the IC50 values were
 
reduced from 26.7 to 8.3 nmol/L for the 
MCF-7-treated cells,
 
from 1.2 to 0.6 nmol/L for the NCI-H460-treated cells, and from
 
6.6 to 1.2 nmol/L for the 
SF-268-treated cells. The greatest
 
magnitude of enhanced potency was in the SF268 cell line (5.7-fold),
 
and a 1- 
to 3-fold increase in potency was observed in the others.
 
Importantly, low nanomolar to subnanomolar IC50s 
were observed
 
for the cell lines, with a 0.64 nmol/L IC50 for the NCI-H460
 
lung cancer cells.
 
 
Influence of dendrimer on camptothecin cellular uptake and retention
 
with MCF-7 breast 
adenocarcinoma cells. Finally, the intracellular
 
accumulation and retention of 10HCPT with and without 
dendrimer
 
encapsulation was measured to help elucidate the potential mechanism
 
underlying the dendrimer-
mediated enhancement of cytotoxic potency.
 
In the first set of trials, the cellular uptake of both free
 
and 
dendrimer-encapsulated 10HCPT was measured. The MCF-7 cells
 
were exposed to medium containing free 
10HCPT or dendrimer-encapsulated
 
10HCPT at a drug concentration of 1, 5, or 8 µmol/L. After
 
2, 10, or 24 
hours of exposure, the medium was removed, and
 
the cells were washed with buffer and lysed. The 
concentration
 
of 10HCPT in the cell lysate samples was determined fluorometrically.
 
 
The results displayed in Fig. 6 , show that dendrimer-encapsulated
 
10HCPT was taken up by the cells at a 
significantly greater
 
rate than the free 10HCPT at the same concentration. At the
 
2-hour mark, the dendrimer-
encapsulated 10HCPT showed, on average,
 
a 16-fold greater intracellular 10HCPT concentration than for
 
free 
10HCPT at the same exposure concentration. Even at the
 
10-hour mark, the encapsulated 10HCPT still showed 
approximately
 
eight times the uptake of free 10HCPT at the same exposure concentration.
 
Clearly, 
encapsulation of the 10HCPT within the dendrimer facilitated
 
uptake.
 
 
 
Figure 6. Top, effect of dendrimer encapsulation on MCF-7 cellular uptake of 10HCPT. Cells were exposed to 
medium containing free (dashed lines) or encapsulated (solid lines) 10HCPT at 1, 5, or 8 µmol/L, followed by 
removal of the medium, washing, and lysis of the cells at 2, 10, and 24 hours. The concentration of 10HCPT in 
the cell lysate samples was then determined fluorometrically. Bottom, effect of dendrimer encapsulation on 
retention of 10HCPT in MCF-7 cells. Cells were exposed to medium containing free (dashed lines) or 
encapsulated (solid lines) 10HCPT at 1, 5, or 8 µmol/L, followed by removal of the medium, washing, and the 
addition of drug-free medium at 24 hours. After 0.5, 8, or 32 hours of exposure to the fresh media, the medium 
was removed, the cells washed and lysed together with floating cells pelleted from the media, and the 
concentration of 10HCPT in the cell lysate samples was then determined fluorometrically. Points, mean; bars, 
SD (n = 3). 10HCPT, free drug; 10HCPT-D, dendrimer-encapsulated drug. 
A second set of experiments was done to measure the retention
 
of both free and dendrimer-encapsulated 
10HCPT. In these trials,
 
MCF-7 cells were exposed to medium containing either free or
 
dendrimer-encapsulated 
10HCPT at a concentration of 1, 5, or
 
8 µmol/L for 24 hours. At the end of the 24-hour exposure
 
period, the 
medium was removed and replaced with fresh medium
 
devoid of 10HCPT, free or encapsulated. After 0.5, 8, or 
32
 
hours of exposure to the new media, the new medium was removed,
 
and the cells were washed with buffer 
and lysed. The concentrations
 
of 10HCPT in the cell lysate samples were determined fluorometrically
 
as above. 
As shown in Fig. 6, even after 32 hours, the cells
 
exposed to the dendrimer-encapsulated 10HCPT retained a 
higher
 
amount of 10HCPT than those cells exposed to the same concentration
 
of free drug. In fact, at 32 hours, 
the cells treated with the
 
encapsulated 10HCPT retained 50% of the amount of drug that
 
they contained at 0.5 
hours. For the cells treated with free
 
10HCPT, the cells retained only 35% of the 10HCPT that they
 
contained 
at the 0.5-hour mark. These data show that 10HCPT,
 
when delivered as encapsulated in the dendrimer, is both 
taken
 
up by the cells at a much greater rate and is retained longer
 
than the free 10HCPT. This may be a result of 
the reduced relative
 
rate of drug efflux or simply enhanced relative retention. These
 
results indicate that the 
increased cytotoxicity of the encapsulated
 
10HCPT toward the MCF-7 cells is likely due to higher intracellular
 
levels of 10HCPT as a result of increased uptake and retention. 
 
Conclusion 
The use of dendrimers as drug carriers by encapsulating hydrophobic
 
drugs is a potential method for delivering 
highly active pharmaceutical
 
compounds that may not be in clinical use due to their limited
 
water solubility and 
resulting suboptimal pharmacokinetics.
 
The dendrimers used in these studies are well-defined, single
 
molecular 
weight, polyester macromolecules composed of the natural
 
metabolites, succinic acid and glycerol. The 
encapsulation of
 
two hydrophobic anticancer compounds, 10HCPT and BACPT, was
 
carried out successfully 
using the solvent evaporation method.
 
Encapsulation of the camptothecins within the dendrimer structure
 
was 
confirmed by NMR spectroscopy.
 
 
The dendrimer-encapsulation procedure enhanced the potency of
 
both 10HCPT and BACPT toward human 
cancer cell lines. The magnitude
 
of the enhancement over the DMSO-dissolved formulations was
 
greatest for 
10HCPT in MCF-7 cells and for BACPT in SF-268 cells,
 
and the trends of the two systems are different. The 
most potent
 
formulation was with dendrimer-encapsulated BACPT against lung
 
cancer cells. These data are 
striking and of interest for six
 
reasons. First, using the dendrimer vehicle affords significantly
 
more 
camptothecin uptake than the DMSO formulation. Second,
 
the differential rank order of enhanced potency leads 
us to
 
hypothesize that using the dendrimer affords unique cell-specific
 
uptake/retention characteristics. Third, 
and in support of this
 
hypothesis, one can recall that the sensitivity of HT-29 cells
 
to BACPT was not 
significantly enhanced by the dendrimer whereas
 
sensitivity was enhanced in the other human cancer cell lines
 
(breast, lung, central nervous system). Therefore, we are eager
 
to submit these formulations for the NCI-60 cell 
line screening
 
panel, as we anticipate that COMPARE analysis may reveal a non–camptothecin
 
profile for each 
drug that might be suggestive of greater efficacy
 
in organ systems in which camptothecins may not be under 
investigation
 
currently for clinical applications. Fourth, the dendrimer increases
 
aqueous solubility like DMSO, 
but the increased solubility alone
 
does not account for the observed cytotoxicity profiles, as
 
the DMSO and 
dendrimer preparations afforded different cytotoxicity
 
profiles. Fifth, our initial studies afford formulations with
 
low clinically relevant IC50s for lung cancer cells. Sixth,
 
the dendrimer provides a means to deliver the highly 
active
 
BACPT in a small volume of aqueous solution—a current
 
challenge that limits the preclinical 
development of this potent
 
camptothecin analogue.
 
 
Through drug uptake and retention experiments with MCF-7 cells,
 
it was observed that encapsulation of 
10HCPT within the dendrimer
 
resulted in greater intracellular drug concentration due both
 
to increased uptake 
and improved retention, which collectively
 
provides a rationale for the increased cytotoxicity observed
 
for the 
drug-dendrimer complex. With this information in hand,
 
we can hypothesize on the possible mechanism(s) for 
the increased
 
uptake and resulting cytotoxicity of the camptothecins when
 
using the dendrimer carrier. The 
dendrimer could be acting as
 
(a) a depot for the camptothecin which releases the camptothecin
 
into the aqueous 
solution over time for subsequent uptake by
 
the cells—but this proposal is not consistent with the
 
data observed 
between cell lines and the DMSO controls; (b)
 
a vehicle that transports the camptothecin to the cell membrane
 
for subsequent passive absorption of the camptothecin or the
 
camptothecin-dendrimer complex via the 
intracellular junctions—although
 
this transport route is generally accepted for smaller materials
 
of <1.5 nm (48); 
or (c) a vehicle and its cargo that is taken
 
up by the endocytosis pathway. The last proposal is more likely
 
and 
would be consistent with reports on anionic carboxylated
 
PAMAM and hydroxyl terminated PAMAM 
dendrimers which are proposed
 
to enter the cell through fluid-phase endocytosis (49, 50).
 
Cell trafficking 
studies with labeled dendrimer with and without
 
the camptothecin are planned to elucidate the role of the 
dendrimer
 
in the delivery of camptothecins.
 
 
In summary, the delivery of hydrophobic molecules, such as the
 
camptothecins, can be accomplished using 
these biodegradable,
 
biocompatible dendrimers that increase aqueous solubility by
 
approximately an order of 
magnitude without the introduction
 
of additional functional groups or other compounds to the formulation
 
that 
may present unwanted effects. Thus, these results may provide
 
a reason to reinvestigate once promising 
anticancer compounds,
 
which may not have been developed because these compounds could
 
not be formulated 
for preclinical evaluation, let alone clinical
 
use. Moreover, the dendrimer enhances both the uptake and 
retention
 
of these compounds within cancer cells, a finding that was not
 
anticipated at the onset of these studies. 
This also opens up
 
new avenues of research into the further development of drug-dendrimer
 
complexes specific 
for a cancer and/or targeted organ system.
 
These encouraging results provide further impetus to design,
 
synthesize, and evaluate dendritic polymers for use in basic
 
drug delivery studies and eventually in the clinic.
 
 
Acknowledgments 
Grant support: In part by the Johnson and Johnson Focused Giving
 
Program and the NIH. Partial support via a 
Research Scholar
 
Grant (RSG-02-024-01-CDD) from the American Cancer Society (N.H.
 
Oberlies) and NIH 
grant R01 CA104286 from The National Cancer
 
Institute (D.J. Kroll).
 
 
The costs of publication of this article were defrayed in part
 
by the payment of page charges. This article must 
therefore
 
be hereby marked advertisement in accordance with 18 U.S.C.
 
Section 1734 solely to indicate this fact.
 
 
The authors wish to thank Anthony Ribeiro for help with the
 
NMR experiments.
 
 
References 
1. Anonymous. Cancer facts & figures 2002–2005 American Cancer Society. Available from: 
http://www.cancer.org, 2002.  
2. Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prod 
1997;60:52–60. 
3. Wall M, Wani M, Cook C, Palmer K, McPhail AT, Sim GA. Plant antitumor agents. I. The isolation and 
structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca 
acuminata. J Am Chem Soc 1966;88:3888–90.  
4. Oberlies NH, Kroll DJ. Camptothecin and taxol: historic achievements in natural products research. J 
Nat Prod 2004;67:129–35. 
5. Sriram D, Yogeeswari P, Thirumurugan R, Bal TR. Camptothecin and its analogues: a review on their 
chemotherapeutic potential. Nat Prod Res 2005;19:393–412. 
6. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: current perspectives. Bioorg Med Chem Lett 
2004;12:1585–604.  
7. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and 
continued development of the camptothecins. Clin Cancer Res 2002;8:641–61.  
8. Del Bino GD, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 
1991;193:27–35. 
9. Ma MK, McLeod HL. Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 
2003;10:41–9. 
10. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the 
anticancer drug camptothecin. Cancer Res 1988;48:1722–6.  
11. Uehara Y. Natural product origins of Hsp90 inhibitors. Curr Cancer Drug Targets 2003;3:325–30. 
12. Hatefi A, Amsden B. Camptothecin delivery methods. Pharm Res 2002;19:1389–99. 
13. Hecht J. Gastrointestinal toxicity of irinotecan. Oncology 1998;12:72–8.  
14. Armstrong DK. Topotecan dosing guidelines in ovarian cancer: reduction and management of 
hematologic toxicity. Oncologist 2004;9:33–42.  
15. Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug 
conjugates. Adv Drug Deliv Rev 2003;55:217–50. 
16. Driver RW, Yang LX. Synthesis and pharmacology of new camptothecin drugs. Mini Rev Med Chem 
2005;5:425–39. 
17. Kopecek J. Soluble biomedical polymers. Polym Med 1977;7:191–221.  
18. Uhrich KE, Cannizzaro SM, Langer R, Shakesheff KM. Polymeric systems for controlled drug release. 
Chem Rev 1999;99:3181–98. 
19. Boas U, Christensen JB, Heegaard PMH. Dendrimers in medicine and biotechnology. Cambridge (UK): 
RSC Publishing; 2006.  
20. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug 
Deliv Rev 2005;57:2106–29. 
21. Schultz LG, Zimmerman SC. Dendrimers: potential drugs and drug delivery agents. Pharm News 
1999;6:25–9.  
22. Liu H, Farrell S, Uhrich KE. Drug release characteristics of unimolecular polymer micelles. J Control 
Release 2000;68:167–74. 
23. Liu M, Kono K, Fréchet JMJ. Water-soluble dendritic unimolecular micelles: their potential as drug 
delivery agents. J Control Release 2000;65:121–31. 
24. Malik N, Wimattanapatapee R, Klopsch R, et al. Dendrimers: relationship between structure and 
biocompatibility in vitro, and preliminary studies on the biodistribution of I-125-labelled 
polyamidoamine dendrimers in vivo. J Control Release 2000;65:133–48. 
25. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery 
and biomedical applications. Drug Discov Today 2001;6:427–36. 
26. Liu MJ, Frechet JMJ. Designing dendrimers for drug delivery. Pharm Sci Technol Today 1999;2:393–
401. 
27. Jansen J, Debrabandervandenberg EMM, Meijer EW. Encapsulation of guest molecules into a dendritic 
box. Science 1994;266:1226–9.  
28. Naylor A, Goddard W, Kiefer G, Tomalia D. Starburst dendrimers. Molecular shape control. J Am 
Chem Soc 1989;111:2339–41.  
29. Pistolis G, Malliaris A. Study of poly(propylene imine) dendrimers in water, by exciplex formation. 
Langmuir 2002;18:246–51.  
30. Hawker CJ, Wooley KL, Fréchet JMJ. Unimolecular micelles and globular amphiphiles: dendritic 
macromolecules as novel recyclable solubilization agents. J Chem Soc [Perkin 1] 1993;12:1287–97.  
31. Richter-Egger D, Tesfai A, Tucker S. Spectroscopic investigations of poly(propyleneimine) dendrimers 
using the solvatochromic probe phenol blue and comparisons to poly(amidoamine) dendrimers. Anal 
Chem 2001;73:5743–51. 
32. Yokoyama S, Otomo A, Mashiko S. Laser emission from high-gain media of dye-doped dendrimer. 
Appl Phys Lett 2002;80:7–9.  
33. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. Drug complexation, in vitro release and cellular 
entry of dendrimers and hyperbranched polymers. Int J Pharm 2003;259:143–60. 
34. Carnahan MA, Grinstaff MW. Synthesis and characterization of poly(glycerol-succinic acid) 
dendrimers. Macromolecules 2001;34:7648–55.  
35. Carnahan MA, Middleton C, Kim J, Kim T, Grinstaff MW. Hybrid dendritic-linear polyester-ethers for 
in situ photopolymerization. J Am Chem Soc 2002;124:5291–3. 
36. Luman NR, Grinstaff MW. Synthesis and aqueous aggregation properties of amphiphilic surface-block 
dendrimers. Org Lett 2005;7:4863–6. 
37. Söntjens SHM, Nettles DL, Carnahan MA, Setton LA, Grinstaff MW. Biodendrimer-based hydrogel 
scaffolds for cartilage tissue repair. Biomacromolecules 2006;7:310–6. 
38. Carnahan MA, Grinstaff MW. Synthesis of generational polyester dendrimers derived from glycerol and 
succinic or adipic acids. Macromolecules 2006;39:609–16.  
39. Grinstaff MW. Biodendrimers: new polymeric materials for tissue engineering. Chemistry 2002;8:2839–
46. 
40. Velazquez AJ, Carnahan MA, Kristinsson J, Stinnett S, Grinstaff MW, Kim T. New dendritic adhesives 
for sutureless ophthalmic surgeries: in vitro studies of corneal laceration repair. Arch Ophthalmol 
2004;122:867–70.  
41. Kang C, Carnahan MA, Wathier M, Grinstaff MW, Kim T. Novel tissue adhesives to secure laser in situ 
Keratomileusis flaps. J Cataract Refract Surg 2005;31:1208–12. 
42. Wathier M, Jung PJ, Carnahan MA, Kim T, Grinstaff MW. Dendritic macromers as in situ polymerizing 
biomaterials for securing cataract incisions. J Am Chem Soc 2004;126:12744–5. 
43. Morgan MT, Carnahan MA, Immoos CE, et al. Dendritic molecular capsules for hydrophobic 
compounds. J Am Chem Soc 2003;125:15485–9. 
44. Wani MC, Wall ME. Plant antitumor agents. II. The structure of two new alkaloids from Camptotheca 
acuminata. J Org Chem 1968;34:1364–7.  
45. Adams DJ, da Silva MW, Flowers JL, et al. Camptothecin analogs with enhanced activity against human 
breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex. 
Cancer Chemother Pharmacol 2006;57:135–44. 
46. Alali FQ, El-Elimat T, Li C, et al. New colchicinoids from a native Jordanian meadow saffron, 
Colchicum brachyphyllum: isolation of the first naturally occurring dextrorotatory colchicinoid. J Nat 
Prod 2005;68:173–8. 
47. Kroll DJ, Rowe TC. Phosphorylation of DNA topoisomerase II in a human tumor cell line. J Biol Chem 
1991;266:7957–61.  
48. Nellans HN. Paracellular intestinal transport: modulation of adsorption. Adv Drug Deliv Rev 
1991;7:339–64.  
49. Wiwattanapatapee R, Carreno-Gomez B, Malik N, Duncan R. Anionic PAMAM dendrimers rapidly 
cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res 2000;17:991–8. 
50. Kohle P, Khandare J, Pillai O, Kannan S, Lieh-Lai M, Kannan RM. Preparation, cellular transport, and 
activity of polyamidoamine-based dendritic nanodevices with high drug payload. Biomaterials 
2006;27:660–9. 
 
 
 
